Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings
Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于召开2025年第一次临时股东大会的通知 | 2025-09-10 | Chinese | |
| 关于修订H股发行并上市后适用的《公司章程（草案）》及相关内部治理制度的公告 | 2025-09-10 | Chinese | |
| 贝达药业股份有限公司对外投资管理制度（草案）（2025年9月） | 2025-09-10 | Chinese | |
| 关于注射用MCLA-129与盐酸恩沙替尼胶囊联用治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2025-09-10 | Chinese | |
| 贝达药业股份有限公司募集资金管理制度（草案）（2025年9月） | 2025-09-10 | Chinese | |
| 贝达药业股份有限公司关联（连）交易决策制度（草案）（2025年9月） | 2025-09-10 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 37811258 | 关于召开2025年第一次临时股东大会的通知 | 2025-09-10 | Chinese | ||
| 37811247 | 关于修订H股发行并上市后适用的《公司章程（草案）》及相关内部治理制度的公告 | 2025-09-10 | Chinese | ||
| 37811245 | 贝达药业股份有限公司对外投资管理制度（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811235 | 关于注射用MCLA-129与盐酸恩沙替尼胶囊联用治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2025-09-10 | Chinese | ||
| 37811223 | 贝达药业股份有限公司募集资金管理制度（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811221 | 贝达药业股份有限公司关联（连）交易决策制度（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811213 | 贝达药业股份有限公司对外担保制度（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811203 | 贝达药业股份有限公司董事会专门委员会工作细则（2025年9月） | 2025-09-10 | Chinese | ||
| 37811199 | 贝达药业股份有限公司境外发行证券与上市相关保密和档案管理工作制度（2025年9月） | 2025-09-10 | Chinese | ||
| 37811187 | 贝达药业股份有限公司独立董事工作制度（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811177 | 贝达药业股份有限公司董事会议事规则（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811176 | 关于聘请H股发行并上市审计机构的公告 | 2025-09-10 | Chinese | ||
| 37811163 | 关于筹划发行H股股票并在香港联合交易所有限公司上市的提示性公告 | 2025-09-10 | Chinese | ||
| 37811154 | 贝达药业股份有限公司章程（草案）（2025年9月） | 2025-09-10 | Chinese | ||
| 37811148 | 第四届监事会第二十三次会议决议公告 | 2025-09-10 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Betta Pharmaceuticals Co.,Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55541/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55541 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55541 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55541 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55541}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Betta Pharmaceuticals Co.,Ltd (id: 55541)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.